Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T

NMR in Biomedicine

Volumn 22, Issue 4, 2009, Pages 405-413

  Tyler, Damian J ^a   Emmanuel, Y ^a,b   Cochlin, L E ^a,b   Hudsmith, L E ^b   Holloway, C J ^a,b   Neubauer, S ^b   Clarke, K ^a   Robson, M D ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

3 T; Cardiac; Magnetic resonance spectroscopy; Phosphorus; Reproducibility

Indexed keywords

3 T; ABSOLUTE DIFFERENCE; ACQUISITION PROTOCOLS; ANALYSIS METHOD; ANATOMICAL LOCATIONS; CARDIAC; CARDIAC MAGNETIC RESONANCE; CHEMICAL SHIFT IMAGING; COEFFICIENT OF VARIATION; CORRELATION COEFFICIENT; FIELD STRENGTHS; HIGH QUALITY; HIGH SPECIFICITY; INTEROBSERVER VARIABILITY; INTRA-OBSERVER VARIABILITY; POTENTIAL USERS; REPRODUCIBILITIES; REPRODUCIBILITY; ROBUST ANALYSIS; SINGLE OBSERVER; SPATIAL RESOLUTION; SPECTRAL INFORMATION;

ADENOSINETRIPHOSPHATE; CHANNEL STATE INFORMATION; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE DETECTORS; PHOSPHATES; PHOSPHORUS; SPECTRUM ANALYSIS;

QUALITY CONTROL;

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; PHOSPHORUS;

ADULT; ARTICLE; CORRELATION COEFFICIENT; HEART MUSCLE; HUMAN; HUMAN EXPERIMENT; IMAGE PROCESSING; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVER VARIATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; THREE DIMENSIONAL IMAGING; HEART; HISTOLOGY; METABOLISM; SAMPLE SIZE;

ADENOSINE TRIPHOSPHATE; HEART; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OBSERVER VARIATION; PHOSPHOCREATINE; PHOSPHORUS ISOTOPES; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE;

EID: 67649202141     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1350     Document Type: Article

References (37)

1. Lamb H, van der Meer RW, de Roos A, Bax JJ. Cardiovascular molecular MR imaging. Eur. J. Nucl. Med. Mol. Imaging 2007; 34 (Suppl 1): S99-S104.
2. Neubauer S, Horn M, Hahn D, Kochsiek KT. Clinical cardiac magnetic resonance spectroscopy - present state and future directions. Mol. Cell. Biochem. 1998; 184(1-2): 439-443.
3. Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary-artery disease by P-31 magnetic-resonance spectroscopy. Circulation 1995; 92(1): 15-23.
4. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GAJ, Lackner K, Ertl G. P-31 magnetic-resonance spectroscopy in dilated cardiomyopathy and coronary-artery disease - altered cardiac high-energy phosphate-metabolism in heart-failure. Circulation 1992; 86(6): 1810-1818.
5. Weiss R, Bottomley P, Hardy C, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N. Engl. J. Med. 1990; 323(23): 1593-1600.
6. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JWA, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J. Am. College Cardiol. 2003; 42(2): 328-335.
7. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003; 107(24): 3040-3046.
8. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. College Cardiol. 2003; 41(10): 1776-1782.
9. Bottomley P, Herfkens R, Smith L, Bashore T. Altered phosphate metabolism in myocardial infarction: P-31 MR spectroscopy. Radiology 1987; 165(3): 703-707.
10. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by P-31 magnetic-resonance spectroscopy. Lancet 1991; 338(8773): 973-976.
11. Hove MT, Neubauer S. MR spectroscopy in heart failure - clinical and experimental findings. Heart Failure Rev. 2007; 12(1): 48-57.
12. Conway MA, Bottomley PA, Ouwerkerk R, Radda GK, Rajagopalan B. Mitral regurgitation - Impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 1998; 97(17): 1716-1723.
13. Neubauer S, Horn M, Pabst T, Harre K, Stromer H, Bertsch G, Sandstede J, Ertl G, Hahn D, Kochsiek K. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by P-31-magnetic resonance spectroscopy. J. Invest. Med. 1997; 45(8): 453-462.
14. Lodi R, Hart PE, Rajagopalan B, Taylor DJ, Crilley JG, Bradley JL, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 2001; 49(5): 590-596.
15. Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 2005; 62(4): 621-626.
16. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure 10.1093/eurheartj/ehi816. Eur. Heart J. 2006; 27(8): 942-948.
17. Hetherington HP, Luney DJE, Vaughan JT, Pan JW, Ponder SL, Tschendel O, Twieg DB, Pohost GM. 3D P-31 spectroscopic imaging of the human heart at 4.1-T. Magn. Reson. Med. 1995; 33(3): 427-431.
18. Menon RS, Hendrich K, Hu XP, Ugurbil K. P-31 NMR-spectroscopy of the human heart at 4-T - detection of substantially uncontaminated cardiac spectra and differentiation of subepicardium and subendocardium. Magn. Reson. Med. 1992; 26(2): 368-376.
19. Tyler DJ, Hudsmith LE, Clarke K, Neubauer S, Robson MD. A comparison of cardiac phosphorus (31P) MR spectroscopy at 1.5 and 3 Tesla. NMR Biomed. 2008; 21(8): 793-798.
20. Tyler DJ, Hudsmith LE, Neubauer S, Clarke K, Robson MD. Comparison of cardiac phosphorous spectroscopy at 1.5T and 3T. Proceedings of International Society of Magnetic Resonance in Medicine, Seattle, USA, 2006.
21. Bottomley PA. MR spectroscopy of the human heart: the status and the challenges. Radiology 1994; 191(3): 593-612.
22. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998; 97(25): 2536-2542.
23. Lamb HJ, Doornbos J, den Hollander JA, Luyten PR, Beyerbacht HP, van der Wall EE, de Roos A. Reproducibility of human cardiac 31P-NMR spectroscopy. NMR Biomed. 1996; 9(5): 217-227.
24. Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc. Natl. Acad. Sci. USA 1982; 79(11): 3523-3526.
25. Frahm J, Haase A, Matthaei D. Rapid NMR imaging of dynamic processes using the FLASH technique. Magn. Reson. Med. 1986; 3(2): 321-327.
26. Pohmann R, von Kienlin M. Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn. Reson. Med. 2001; 45(5): 817-826.
27. Robson MD, Tyler DJ, Neubauer S. Ultrashort TE chemical shift imaging (UTE-CSI). Magn. Reson. Med. 2005; 53(2): 267-274.
28. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105(4): 539-542.
29. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. Magn. Reson. Mater. Phys. Biol. Med. 2001; 12(2-3): 141-152.
30. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput. Biol. Med. 2001; 31(4): 269-286.
31. Bottomley PA, Ouwerkerk R. Optimum flip-angles for exciting NMR with uncertain T-1 values. Magn. Reson. Med. 1994; 32(1): 137-141.
32. Tyler DJ, Hudsmith LE, Neubauer S, Clarke K, Robson MD. Measurement of the longitudinal relaxation time (T1) of cardiac phosphorous metabolites at 3T. Proceedings of International Society of Magnetic Resonance in Medicine, Seattle, USA, 2006.
33. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001; 14(4): 278-283.
34. Bland JM, Altman DG. Statistical-methods for assessing agreement between 2 methods of clinical measurement. Lancet 1986; 1(8476): 307-310.
35. Sidak Z. Rectangular confidence regions for means of multivariate normal distributions. J. Am. Stat. Assoc. 1967; 62(318): 626-633.
36. {31}SP NMR spectroscopy. Science 1985; 229(4715): 769-772.
37. Ordidge RJ, Connelly A, Lohman JAB. Image-selected in vivo spectroscopy (ISIS) - a new technique for spatially selective NMR-spectroscopy. J. Magn. Reson. 1986; 66(2): 283-294.